BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.93 USD | +1.30% |
|
+1.35% | -4.64% |
ETFs positioned on Bristol-Myers Squibb Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 215 M€ | +13.63% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 18 M€ | +1.40% | - | |
| 2.63% | 23 M€ | +6.86% | - | |
| 2.37% | 2 M€ | -25.75% | ||
| 2.29% | 32 M€ | -0.67% | - | |
| 2.08% | 9 M€ | -.--% | - | |
| 1.90% | 16 M€ | -3.37% | ||
| 1.85% | 2 M€ | +5.19% | ||
| 1.43% | 5 M€ | -72.95% | - | |
| 1.42% | 9 M€ | -4.31% | - | |
| 1.37% | 26 M€ | +16.85% | - | |
| 1.26% | 846 M€ | +1.93% | ||
| 1.00% | 96 M€ | -4.48% | ||
| 0.99% | 10 M€ | +2.95% | ||
| 0.83% | 105 M€ | +3.54% | ||
| 0.82% | 8 M€ | -.--% | ||
| 0.80% | 2,510 M€ | +8.60% | ||
| 0.78% | 3 M€ | +15.16% | - | |
| 0.78% | 13 M€ | -.--% | - |
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
48.3
USD
Average target price
56.33
USD
Spread / Average Target
+16.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.64% | 97.89B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- BMY Stock
- Funds and ETFs Bristol-Myers Squibb Company
